RU2494745C2 - Iрнк средство для снижения уровней вирусного белка, мрнк или титра респираторного синцитиального вируса в клетке дыхательных путей - Google Patents

Iрнк средство для снижения уровней вирусного белка, мрнк или титра респираторного синцитиального вируса в клетке дыхательных путей Download PDF

Info

Publication number
RU2494745C2
RU2494745C2 RU2010139908/10A RU2010139908A RU2494745C2 RU 2494745 C2 RU2494745 C2 RU 2494745C2 RU 2010139908/10 A RU2010139908/10 A RU 2010139908/10A RU 2010139908 A RU2010139908 A RU 2010139908A RU 2494745 C2 RU2494745 C2 RU 2494745C2
Authority
RU
Russia
Prior art keywords
sirna
rsv
irna agent
irna
virus
Prior art date
Application number
RU2010139908/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2010139908A (ru
Inventor
Сайлен БАРИК
Original Assignee
Саут Алабама Медикал Сайенс Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саут Алабама Медикал Сайенс Фаундейшн filed Critical Саут Алабама Медикал Сайенс Фаундейшн
Publication of RU2010139908A publication Critical patent/RU2010139908A/ru
Application granted granted Critical
Publication of RU2494745C2 publication Critical patent/RU2494745C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
RU2010139908/10A 2004-10-22 2005-10-21 Iрнк средство для снижения уровней вирусного белка, мрнк или титра респираторного синцитиального вируса в клетке дыхательных путей RU2494745C2 (ru)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62155204P 2004-10-22 2004-10-22
US60/621,552 2004-10-22
US11/151,976 US20060089324A1 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,893 US7592322B2 (en) 2004-10-22 2005-06-14 RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
US11/151,976 2005-06-14
US11/151,893 2005-06-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2007115097/10A Division RU2409666C2 (ru) 2004-10-22 2005-10-21 Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение

Publications (2)

Publication Number Publication Date
RU2010139908A RU2010139908A (ru) 2012-04-10
RU2494745C2 true RU2494745C2 (ru) 2013-10-10

Family

ID=36578352

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010139908/10A RU2494745C2 (ru) 2004-10-22 2005-10-21 Iрнк средство для снижения уровней вирусного белка, мрнк или титра респираторного синцитиального вируса в клетке дыхательных путей

Country Status (12)

Country Link
US (2) US7592322B2 (enExample)
EP (1) EP1806968B1 (enExample)
JP (1) JP5037349B2 (enExample)
KR (1) KR101193825B1 (enExample)
CN (1) CN101087527B (enExample)
AU (1) AU2005314617B2 (enExample)
BR (1) BRPI0517286A (enExample)
CA (1) CA2584309A1 (enExample)
MX (1) MX2007004692A (enExample)
NO (1) NO20071953L (enExample)
RU (1) RU2494745C2 (enExample)
WO (1) WO2006062596A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2474910A1 (en) 2002-02-01 2003-08-07 Sequitur, Inc. Oligonucleotide compositions with enhanced efficiency
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
WO2003064621A2 (en) 2002-02-01 2003-08-07 Ambion, Inc. HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US8258288B2 (en) * 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
WO2006085987A2 (en) * 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
US7790878B2 (en) * 2004-10-22 2010-09-07 Alnylam Pharmaceuticals, Inc. RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
EP1833490A4 (en) * 2005-01-07 2010-09-15 Alnylam Pharmaceuticals Inc INTERFERING RNA MODULATION OF SYNCYTIAL RESPIRATORY VIRUS AND THERAPEUTIC USES THEREOF
PL2308514T3 (pl) 2007-03-23 2013-11-29 To Bbb Holding B V Koniugaty do ukierunkowanego dostarczania leku poprzez barierę krew-mózg
EP2152316A4 (en) * 2007-04-26 2011-03-23 Quark Pharmaceuticals Inc THERAPEUTIC DELIVERY OF INHIBITORY NUCLEIC ACID MOLECULES IN THE RESPIRATORY SYSTEM
WO2009055445A2 (en) * 2007-10-22 2009-04-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF RESPIRATORY SYNCYTIAL VIRUS (RSV) EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2009076679A2 (en) * 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
JP2011528910A (ja) * 2008-07-25 2011-12-01 アルニラム ファーマスーティカルズ インコーポレイテッド センス鎖中の一般塩基またはミスマッチを使用したｓｉＲＮＡサイレンシング活性の亢進
WO2010048590A1 (en) * 2008-10-23 2010-04-29 Alnylam Pharmaceuticals, Inc. Methods and compositions for prevention or treatment of rsv infection using modified duplex rna molecules
ES2528010T5 (es) * 2010-03-08 2018-02-19 Novartis Ag Métodos para detectar la presencia de patógenos intracelulares
WO2012118911A1 (en) * 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
WO2012138416A1 (en) 2011-04-08 2012-10-11 Bio-Rad Laboratories, Inc. Pcr reaction mixtures with decreased non-specific activity
US11163898B2 (en) * 2013-09-11 2021-11-02 Mimecast Services Ltd. Sharing artifacts in permission-protected archives
IL292575A (en) 2014-09-07 2022-06-01 Selecta Biosciences Inc Methods and preparations for weakening immune responses by modulating gene expression in an antiviral transfer system
US10894966B2 (en) 2014-09-26 2021-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-based expression vectors and uses thereof
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
AU2020284555A1 (en) 2019-05-28 2021-12-23 Selecta Biosciences, Inc. Methods and compositions for attenuated anti-viral transfer vector immune response
EP4119164A4 (en) * 2020-03-13 2024-07-10 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. ANTI-CORONAVIRUS EFFECT AND APPLICATION OF PI4K INHIBITOR
EP4162050A1 (en) * 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
EP4527927A1 (en) * 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014792A2 (en) * 1995-10-17 1997-04-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
EA012573B1 (ru) * 2005-01-07 2009-10-30 Элнилэм Фармасьютикалз, Инк. РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US5693532A (en) * 1994-11-04 1997-12-02 Ribozyme Pharmaceuticals, Inc. Respiratory syncytial virus ribozymes
US6214805B1 (en) * 1996-02-15 2001-04-10 The United States Of America As Represented By The Department Of Health And Human Services RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5898031A (en) * 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
EP1390472A4 (en) * 2001-05-29 2004-11-17 Sirna Therapeutics Inc NUCLEIC ACID TREATMENT OF DISEASES OR SIDES RELATED TO RAS, HER2 AND HIV LEVELS
WO2003008628A2 (en) 2001-07-20 2003-01-30 Ribozyme Pharmacuticals, Inc. Enzymatic nucleic acid peptide conjugates
US20030203356A1 (en) * 2002-01-22 2003-10-30 The Cleveland Clinic Foundation RNase L activator-antisense complexes
US20040204420A1 (en) * 2002-08-05 2004-10-14 Rana Tariq M. Compounds for modulating RNA interference
AU2003279010A1 (en) * 2002-09-28 2004-04-19 Massachusetts Institute Of Technology Compositions and methods for delivery of short interfering rna and short hairpin rna
US20040242518A1 (en) 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
KR20050083855A (ko) * 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
ATE477337T1 (de) * 2003-01-16 2010-08-15 Univ Pennsylvania Zusammensetzungen und verfahren zur sirna-hemmung von icam-1
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
EP2239329A1 (en) 2003-03-07 2010-10-13 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
CA2522349A1 (en) 2003-04-17 2004-11-04 Alnylam Pharmaceuticals, Inc. Protected monomers
CA2522637C (en) 2003-04-17 2014-01-21 Alnylam Pharmaceuticals, Inc. Modified irna agents
US20070238676A1 (en) * 2003-12-04 2007-10-11 Mohapatra Shyam S Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997014792A2 (en) * 1995-10-17 1997-04-24 Hybridon, Inc. Oligonucleotides with anti-respiratory syncytial virus activity
US20030203868A1 (en) * 2002-02-06 2003-10-30 Bushman Frederic D. Inhibition of pathogen replication by RNA interference
EA012573B1 (ru) * 2005-01-07 2009-10-30 Элнилэм Фармасьютикалз, Инк. РНКi МОДУЛЯЦИЯ RSV И ЕЁ ТЕРАПЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VIRA BITKO et al., Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses, BMC Microbiology, 20 December 2001, Vol.1, p.p.1-11. *

Also Published As

Publication number Publication date
JP2008517940A (ja) 2008-05-29
KR20070106686A (ko) 2007-11-05
HK1114308A1 (en) 2008-10-31
EP1806968A4 (en) 2010-06-02
AU2005314617A1 (en) 2006-06-15
US20060089323A1 (en) 2006-04-27
CN101087527B (zh) 2012-01-18
RU2010139908A (ru) 2012-04-10
KR101193825B1 (ko) 2012-10-23
US7592322B2 (en) 2009-09-22
WO2006062596A2 (en) 2006-06-15
NO20071953L (no) 2007-05-18
JP5037349B2 (ja) 2012-09-26
CA2584309A1 (en) 2006-06-15
CN101087527A (zh) 2007-12-12
BRPI0517286A (pt) 2008-10-07
MX2007004692A (es) 2007-09-07
EP1806968B1 (en) 2012-12-05
WO2006062596A3 (en) 2007-05-18
US20060089324A1 (en) 2006-04-27
AU2005314617B2 (en) 2011-05-26
EP1806968A2 (en) 2007-07-18

Similar Documents

Publication Publication Date Title
RU2494745C2 (ru) Iрнк средство для снижения уровней вирусного белка, мрнк или титра респираторного синцитиального вируса в клетке дыхательных путей
KR101169668B1 (ko) ＲＳＶ의 ＲＮＡｉ 조절 및 이를 위한 약제학적 조성물
US7790878B2 (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
WO2009076679A2 (en) Methods and compositions for prevention or treatment of rsv infection
RU2409666C2 (ru) Модуляция rsv, piv и других респираторных вирусов с помощью rnai и ее применение
HK1114308B (en) Rnai modulation of rsv, piv and other respiratory viruses and uses thereof
NZ554494A (en) RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof
HK1144102A1 (en) Rnai modulation of rsv and therapeutic uses thereof
HK1144102B (en) Rnai modulation of rsv and therapeutic uses thereof

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20141022